Revolution Medicines (RVMD) Insider Anthony Sells $353K of Stock

Revolution Medicines, Inc. Chief Global Commercialization Officer Anthony Mancini sold 1,774 shares of the company's stock on September 16, 2026. The transaction was revealed in a Form 4 filed with the Securities and Exchange Commission.

RVMD Revolution Medicines, Inc.

$177.96 ▲ +125.21% year to date

1M 3M YTD

Daily close · Oct 16, 2026

Inside Anthony Mancini's Revolution Medicines Trade

Mancini executed the sale of 1,774 shares at an average price of $199.24 per share, bringing the total value of the transaction to $353,449.10. This sale was carried out pursuant to a pre-arranged Rule 10b5-1 trading plan. On the day of the transaction, Revolution Medicines stock closed at $195.92.

Other Institutional Activity in Revolution Medicines

Farallon Capital Management LLC reduced its holdings by 54,421 shares, ending with 13,550,796 shares worth about $2.41 billion. Baker Bros. Advisors, LP grew its holdings by 1,888,116 shares, ending with 11,443,357 shares worth about $2.04 billion. Jupiter Topco LLC grew its holdings by 5,368,072 shares, ending with 10,736,145 shares worth about $1.91 billion. Darwin Global Management, Ltd. grew its holdings by 8,418,823 shares, ending with 10,629,822 shares worth about $1.89 billion. Nextech Invest, Ltd. kept its holdings unchanged, ending with 7,601,087 shares worth about $1.35 billion.

Revolution Medicines, Inc. Stock Down 3.8%

Revolution Medicines shares recently traded around $182.01 as of October 16, 2026. The stock closed at $195.92 on the day of the insider trade.

Recent Earnings

Revolution Medicines reported a trailing-twelve-month earnings per share of negative $8.87. The company's next earnings report is scheduled for November 4, 2026.

Insider Buying and Selling at Revolution Medicines, Inc.

Earlier, on June 18, 2026, Sushil Patel bought 3,127 shares. Later, Chief Financial Officer Jack Anders sold 20,000 shares on June 24, 2026, at an average price of $168.33 per share in a deal worth $3.37 million, and acquired 20,000 shares on the same day. Chief Development Officer Alan B. Sandler also sold 341 shares on September 16, 2026, at an average price of $199.24 per share in a transaction worth $67,940.67 under a pre-arranged plan.

Analysts Set New Price Targets

Before the trade, Morgan Stanley initiated coverage on September 10, 2026, with an Overweight rating and a $255.00 price target. After the trade, B of A Securities maintained a Buy rating and raised its price target to $265.00 from $225.00 on September 21, 2026. Brookline Capital initiated a Buy rating with a $318.00 price target on September 28, 2026. Truist Securities maintained a Buy rating and raised its target to $240.00 from $239.00 on October 7, 2026. RBC Capital maintained an Outperform rating and lifted its target to $259.00 from $251.00 on October 8, 2026. The stock carries a consensus Strong Buy recommendation from analysts.

About Revolution Medicines

Revolution Medicines is a Redwood City, California-based biotechnology company focused on the discovery and development of targeted therapies for RAS-addicted cancers. The company works on clinical-stage precision oncology treatments designed to address hard-to-treat tumors.

Bottom Line

Investors will watch for the upcoming financial results on November 4, 2026. Insider transactions executed under pre-arranged plans are common among corporate officers managing personal holdings.